 Corporate Counsel | Bristol-Myers Targets Heart-Failure Drugs in R&D Effort Bloomberg (BMY), pouring resources into new immune system-based cancer drugs, said it also plans to expand development of treatments for congestive heart failure and fibrosis. The drugmaker also isn't ready to give up on therapies for the neurodegenerative ... Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology with ... |
